[(1R,2S,6R,10S,11R,13S,14R)-13-acetyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12-trimethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(1R,2S,6R,10S,11R,13S,14R)-13-acetyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12-trimethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate
• 化学式: C₃₅H₅₄O₈
• 分子量: 602.8
• InChiKey: FXEDIXLHKQINFP-TWPWPRQLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  43
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20140187510A1

  公开（公告）日：2014-07-03

  The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
• TREATMENT OF CNS DISEASE WITH ENCAPSULATED INDUCIBLE CHOROID PLEXUS CELLS
  申请人：Living Cell Technologies New Zealand Limited

  公开号：US20160361365A1

  公开（公告）日：2016-12-15

  Compositions and methods are disclosed that relate to improved treatments for nervous system diseases and disorders using CNS-implanted semi-permeable biocompatible capsules containing encapsulated pathogen-free xenogeneic choroid plexus (CP) cells that are induced to produce altered (and in certain embodiments increased) levels of one or more cerebrospinal fluid (CSF) components. Capsules are selected as disclosed to be capable of induction of elevated CSF production levels by CP cells that are remarkably (>16 months post implant) long-lived, without eliciting immunological rejection, inflammation or foreign body response reactions.